Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). (Q38367232)

2 September 2017

1 reference

title

Renal effects of molecular targeted therapies in oncology: a review by the Cancer and the Kidney International Network (C-KIN). (English)

1 reference

2 September 2017

author

Vincent Launay-Vacher

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Gilberto de Castro

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Stuart M Lichtman

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

Ben Sprangers

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

author name string

M Aapro

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

E Cohen

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

G Deray

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

M Dooley

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

B Humphreys

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

J Rey

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

F Scotté

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

H Wildiers

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

publication date

3 March 2015

1 reference

2 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

4 June 2020

page(s)

1677-1684

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

Chronic kidney disease after nephrectomy in patients with renal cortical tumours: a retrospective cohort study

4 June 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Cancer and renal insufficiency results of the BIRMA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Prevalence of baseline chronic kidney disease in patients presenting with solid renal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Association of CKD and cancer risk in older people

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Changes in causes of death and risk of cancer in Danish patients with autosomal dominant polycystic kidney disease and end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

CKD and the risk of incident cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Spectrum of cancer risk among US solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

VEGF inhibition and renal thrombotic microangiopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Hypertension and proteinuria: a class-effect of antiangiogenic therapies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Home blood-pressure monitoring in patients receiving sunitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Rapid development of hypertension by sorafenib: toxicity or target?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Epidermal growth factor receptor inhibition strategies in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Impact of cetuximab conventional dosing on cetuximab-induced magnesium concentration under haemodialysis in head and neck cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Safety, pharmacokinetics, and activity of ABX-EGF, a fully human anti-epidermal growth factor receptor monoclonal antibody in patients with metastatic renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Effects of the EGFR Inhibitor Erlotinib on Magnesium Handling

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

When EGF is offside, magnesium is wasted

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Cetuximab therapy and symptomatic hypomagnesemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Erlotinib preserves renal function and prevents salt retention in doxorubicin treated nephrotic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Bevacizumab in the treatment of metastatic colorectal cancer (mCRC) in second- and third-line settings

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (H

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Role of renal function on the development of cardiotoxicity associated with trastuzumab-based adjuvant chemotherapy for early breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Acute kidney injury in patients with severe rash on vemurafenib treatment for metastatic melanomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Spontaneous regression of crizotinib-associated complex renal cysts during continuous crizotinib treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Assessment of vandetanib as an inhibitor of various human renal transporters: inhibition of multidrug and toxin extrusion as a possible mechanism leading to decreased cisplatin and creatinine clearance

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Interactive medical case. An unusual case of abdominal pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

OPG/RANK/RANKL signaling system and its significance in nephrology

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Interaction of vascular and bone disease in patients with normal renal function and patients undergoing dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Localization of RANKL (receptor activator of NF kappa B ligand) mRNA and protein in skeletal and extraskeletal tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Sorafenib and everolimus in advanced clear cell renal carcinoma: a phase I/II trial of the SCRI Oncology Research Consortium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Safety of everolimus by treatment duration in patients with advanced renal cell cancer in an expanded access program.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Phase II trial of everolimus for the treatment of nonclear-cell renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Phase 3 trial of everolimus for metastatic renal cell carcinoma : final results and analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Temsirolimus-induced glomerulopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

International Society of Geriatric Oncology (SIOG) recommendations for the adjustment of dosing in elderly cancer patients with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Prevalence of Renal Insufficiency in cancer patients and implications for anticancer drug management

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

Evolution of renal function in patients treated with antiangiogenics after nephrectomy for renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV136

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDV136

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json

release_rsqfpf4tjvgvrcryx2r7k2kbmy

4 June 2020

Fatcat ID

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/rsqfpf4tjvgvrcryx2r7k2kbmy

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25735315%20AND%20SRC:MED&resulttype=core&format=json